Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Roche’s subcutaneous Tecentriq recommended by CHMP for multiple cancer types

The formulation can cut treatment time by approximately 80% compared to intravenous infusion

- PMLiVE

New WHO initiative to prioritise endemic pathogens for vaccine development

Value profiles of 16 pathogens with vaccines in clinical development will be featured

- PMLiVE

Message from the Women in Medicine™ Summit: “Be the Change You Want to See”

What are some of the biggest gaps that women still face in healthcare today?“So many I could talk for hours!” says Shikha Jain, MD, FACP, President, CEO, Founder Women in...

Medscape Education

- PMLiVE

Best practices for building an effective scientific communications platform

By Luis Perez

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

- PMLiVE

Takeda’s enzyme replacement therapy approved by FDA for rare blood clotting disorder

The ultra-rare inherited disease is estimated to affect fewer than 1,000 people in the US

- PMLiVE

GSK’s momelotinib recommended by CHMP to treat myelofibrosis patients with anaemia

About 40% of patients have moderate-to-severe anaemia at the time of diagnosis

- PMLiVE

Redefining medical communications in the age of omnichannel engagement

By Chris Hall

- PMLiVE

Takeda’s Fruzaqla receives FDA approval for metastatic colorectal cancer

More than 150,000 new cases of colorectal cancer will be diagnosed in the US in 2023

- PMLiVE

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

The decision makes Ixchiq, which is administered as a single injection, the world's first licensed vaccine against the mosquito-borne disease

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links